Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights

Rhea-AI Summary

Biomea Fusion (BMEA) released its second quarter 2024 financial results and corporate highlights. The company reported a net loss of $37.3 million for Q2 2024 compared to $24.9 million in Q2 2023. The rise in losses is attributed to increased R&D expenses, which were $31.8 million, up from $21.9 million in Q2 2023, and higher G&A expenses. As of June 30, 2024, the company had cash and equivalents of $113.7 million.

Key milestones include the upcoming readout of COVALENT-111 Phase 2b and COVALENT-112 Phase 2a trials in Q4 2024. Biomea also aims to announce a third program in obesity in Q3 2024. The company is addressing an FDA clinical hold on BMF-219 for diabetes due to potential hepatotoxicity. Initial BMF-219 data for type 1 diabetes shows promising beta-cell function improvements.

Positive

• Initial BMF-219 data shows promising beta-cell improvements for type 1 diabetes.
• Upcoming readout of COVALENT-111 and COVALENT-112 trials scheduled for Q4 2024.

Negative

• Net loss increased to $37.3 million in Q2 2024 from $24.9 million in Q2 2023.
• FDA clinical hold on BMF-219 due to potential drug-induced hepatotoxicity.
• Cash and equivalents decreased to $113.7 million from $177.2 million as of December 31, 2023.

Financial Analyst

Biomea Fusion's Q2 2024 financial results reveal a concerning trend in the company's cash position and operational losses. The cash, cash equivalents and restricted cash decreased from $177.2 million at the end of 2023 to $113.7 million as of June 30, 2024, a significant 35.8% reduction in just six months. This burn rate is alarming and could potentially lead to liquidity issues if not addressed.

The net loss for Q2 2024 increased to $37.3 million, up from $24.9 million in the same period last year, representing a 49.8% increase. This escalation in losses is primarily driven by a substantial rise in R&D expenses, which jumped from $21.9 million to $31.8 million, a 45.2% increase year-over-year. While increased R&D spending can be positive for a clinical-stage biopharmaceutical company, it's important to balance this with available resources and potential revenue streams.

The company's G&A expenses also saw an increase, albeit less dramatic, rising from $5.7 million to $7.1 million. This 24.6% increase in administrative costs during a period of clinical holds and trial delays raises questions about operational efficiency.

Given the current cash position and burn rate, Biomea may need to consider additional financing options in the near future to support its ongoing clinical trials and R&D efforts. The company's ability to advance its pipeline, particularly in light of the FDA clinical hold on its diabetes trials, will be critical for its financial outlook and investor confidence.

Medical Research Analyst

The clinical progress of Biomea Fusion's lead candidate, BMF-219, presents a mixed picture with significant challenges ahead. The FDA's full clinical hold on the COVALENT-111 and COVALENT-112 trials for type 2 and type 1 diabetes, respectively, is a major setback. The hold, based on "deficiencies related to the level of possible drug-induced hepatotoxicity," raises serious safety concerns that could potentially derail or significantly delay the diabetes program.

However, it's noteworthy that initial data from the first two type 1 diabetes patients in COVALENT-112 showed "early signs of clinical activity with improved measures of beta-cell function." This suggests that BMF-219, if proven safe, could have potential efficacy in treating diabetes. The company's ability to address the FDA's concerns and lift the clinical hold will be important for the future of this program.

On a positive note, the company is diversifying its pipeline with a third program in obesity, expected to be announced in Q3 2024. This GLP-1 receptor agonist could potentially tap into the rapidly growing market for obesity treatments, providing a new avenue for growth if successful.

In oncology, Biomea is progressing with multiple trials (COVALENT-101, 102 and 103) targeting both liquid and solid tumors. However, the discontinuation of two cohorts in COVALENT-101 due to insufficient enrollment is concerning and may indicate challenges in patient recruitment or competition in the oncology space.

Overall, while Biomea's pipeline shows promise, the clinical hold on its lead program and the mixed progress across its portfolio suggest a challenging road ahead in bringing these treatments to market.

• COVALENT-111 Phase 2b on track for Q4 2024 readout
• COVALENT-112 Phase 2a on track for Q4 2024 readout
• Announcement of the third program in obesity on track for Q3 2024
  

REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, reported second quarter 2024 financial results and corporate highlights.

“Q2 2024 was another busy quarter for the company. The company’s top priority is working with FDA to resolve the clinical hold for BMF-219 in diabetes. We have made great progress with the second program, BMF-500 and our third program will be announced following the 60^th European Association for the Study of Diabetes (EASD). Topline readout from the Phase 2b of COVALENT-111 with approximately 195 patients is on track for Q4 2024, and the topline readout from the Phase 2a of COVALENT-112 with approximately 20 patients is on track for Q4 2024,” stated Thomas Butler, Biomea Fusion’s Chief Executive Officer and Chairman of the Board.

DIABETES

COVALENT-111 (BMF-219 for Type 2 Diabetes) & COVALENT-112 (BMF-219 for Type 1 Diabetes)

• On June 6, 2024, company announced it received notice from FDA that a full clinical hold has been placed on Biomea’s ongoing Phase I/II clinical trials of the company’s investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively. In its communication, FDA noted deficiencies based on the level of possible drug-induced hepatotoxicity observed in the completed dose escalation phase of COVALENT-111.
• Initial data reported from the first two type 1 diabetes patients dosed with BMF-219 in COVALENT-112 demonstrated early signs of clinical activity with improved measures of beta-cell function after initial treatment with BMF-219. BMF-219 has been generally well tolerated by both patients.

Anticipated Milestones:

• Topline Week 26 data readout of Phase 2b with approximately 195 patients of COVALENT-111 expected for Q4 2024.
• Topline data readout of Phase 2a of COVALENT-112 with approximately 20 patients expected for Q4 2024.

OBESITY

Third Program (Oral, Small Molecule, GLP-1R Agonist)

Anticipated Milestones:

• Announce a third development candidate, a potent, selective, GLP-1 receptor agonist, expected in Q3 2024.
  

ONCOLOGY

COVALENT-101 (BMF-219 for Liquid Tumors)

Anticipated Milestones:

• Complete dose escalation portion of COVALENT-101 expected by year end 2024.
  (Two cohorts, CLL and DLBCL of COVALENT-101 have been discontinued due to insufficient enrollment.)
  

COVALENT-102 (BMF-219 for Solid Tumors)

Anticipated Milestones:

• Complete dose escalation portion of COVALENT-102 expected by year end 2024.
  

COVALENT-103 (BMF-500 for Acute Leukemias)

Anticipated Milestones:

• Complete dose escalation portion of COVALENT-103 expected by year end 2024.
  

FUSION™ SYSTEM DISCOVERY PLATFORM

• Continued the development of the Biomea FUSION™ Platform technology.
  

SECOND QUARTER 2024 FINANCIAL RESULTS

• Cash, Cash Equivalents, and Restricted Cash: As of June 30, 2024, the Company had cash, cash equivalents and restricted cash of $113.7 million, compared to $177.2 million as of December 31, 2023.
• Net Income/Loss: The Company reported a net loss attributable to common stockholders of $37.3 million for the three months ended June 30, 2024, which included $4.8 million of stock-based compensation, compared to a net loss of $24.9 million for the same period in 2023, which included $3.4 million of stock-based compensation. Net loss attributable to common stockholders was $76.3 million for the six months ended June 30, 2024, which included $9.9 million of stock-based compensation, compared to a net loss of $53.9 million for the same period in 2023, which included $6.7 million of stock-based compensation.
• Research and Development (R&D) Expenses: R&D expenses were $31.8 million for the three months ended June 30, 2024, compared to $21.9 million for the same period in 2023. The increase of $9.9 million was primarily due to an increase of $7.2 million related to clinical and $1.6 million related to pre-clinical development cost for the Company’s product candidates, BMF-219 and BMF-500, as well as an increase in personnel-related costs of $1.8 million. R&D expenses were $65.6 million for the six months ended June 30, 2024, compared to $46.3 million for the same period in 2023. The increase of $19.3 million was primarily due to an increase of $11.8 million related to clinical and $2.5 million related to pre-clinical development cost for the Company’s product candidates, BMF-219 and BMF-500, as well as an increase in personnel-related costs of $4.9 million.
• General and Administrative (G&A) Expenses: G&A expenses were $7.1 million for the three months ended June 30, 2024, compared to $5.7 million for the same period in 2023. The increase of $1.4 million was primarily due to increased personnel-related expenses, including stock-based compensation. G&A expenses were $14.4 million for the six months ended June 30, 2024, compared to $11.4 million for the same period in 2023. The increase of $3.0 million was primarily due to an increase of $2.1 million from personnel-related expenses, including stock-based compensation and $1.3 million related to general external consultants and legal related expenses.

About Biomea Fusion

Biomea Fusion is a clinical stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to treat patients with metabolic disease and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response. 

We are utilizing our proprietary FUSION™ System to discover, design and develop a pipeline of next-generation covalent-binding small molecule medicines designed to maximize clinical benefit for patients. We aim to have an outsized impact on the treatment of disease for the patients we serve. We aim to cure.

Visit us at biomeafusion.com and follow us on LinkedIn, Twitter and Facebook.

Forward-Looking Statements

Statements we make in this press release may include statements which are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact, including statements regarding the clinical and therapeutic potential of our product candidates and development programs, including BMF-219 and BMF-500, the potential of BMF-219 as a treatment for type 1 and type 2 diabetes, various types of liquid tumors and leukemia, and KRAS mutant solid tumors, the potential of BMF-500 as a treatment for cancers with a FLT3 mutation, our research, development and regulatory plans, the progress of our ongoing and upcoming clinical trials, including our Phase 1/2 COVALENT-111 study of BMF-219 in type 2 diabetes, our Phase 2 COVALENT-112 study of BMF-219 in type 1 diabetes, our Phase I COVALENT-101 study of BMF-219 in relapsed or refractory acute myeloid leukemia, our Phase 1/1b COVALENT-102 study of BMF-219 in KRAS mutant solid tumors and our Phase 1 COVALENT-103 study of BMF-500 in leukemia, the anticipated enrollment of patients and availability of data from our clinical trials, our plans to address the matters raised in the FDA’s clinical hold letter, our ability to resolve the clinical hold on a timely basis, or at all, our plan to announce a third program in obesity, and the timing of such events, and our expectations regarding the Biomea FUSION™ Platform and our plans to announce a third development candidate, may be deemed to be forward-looking statements. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions.

Any forward-looking statements in this press release are based on our current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including the risk that we may encounter delays in preclinical or clinical development, patient enrollment and in the initiation, conduct and completion of our ongoing and planned clinical trials and other research and development activities. These risks concerning Biomea Fusion’s business and operations are described in additional detail in its periodic filings with the U.S. Securities and Exchange Commission (the “SEC”), including its most recent periodic report filed with the SEC and subsequent filings thereafter. Biomea Fusion explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

- See attached for financial tables -

BIOMEA FUSION, INC. Condensed Statement of Operations and Comprehensive Loss (Unaudited) (in thousands, except share and per share data)
		Three Months Ended								Six Months Ended
		June 30,								June 30,
		2024				2023				2024				2023
Operating expenses:
Research and development (1)		$	31,825			$	21,938			$	65,601			$	46,333
General and administrative (1)			7,073				5,719				14,356				11,355
Total operating expenses			38,898				27,657				79,957				57,688
Loss from operations			(38,898	)			(27,657	)			(79,957	)			(57,688	)
Interest and other income, net			1,622				2,766				3,620				3,746
Net loss		$	(37,276	)		$	(24,891	)		$	(76,337	)		$	(53,942	)
Other comprehensive loss:
Unrealized gain (loss) on investments, net			—				—				—				1
Comprehensive loss		$	(37,276	)		$	(24,891	)		$	(76,337	)		$	(53,941	)
Net loss per common share, basic and diluted		$	(1.03	)		$	(0.70	)		$	(2.12	)		$	(1.66	)
Weighted-average number of shares used to compute basic and diluted net loss per common share			36,043,561				35,348,293				35,966,965				32,483,297

⁽¹⁾ Includes stock-based compensation as follows (non-cash operating expenses):

		Three Months Ended								Six Months Ended
		June 30,								June 30,
		2024				2023				2024				2023
Research and development		$	2,448			$	1,650			$	4,994			$	3,124
General and administrative			2,392				1,786				4,868				3,545
Total stock-based compensation expense		$	4,840			$	3,436			$	9,862			$	6,669

BIOMEA FUSION, INC. Condensed Balance Sheet Data (Unaudited) (in thousands)
		June 30,				December 31,
		2024				2023
Cash, cash equivalents, and restricted cash		$	113,655			$	177,236
Working capital			91,125				156,321
Total assets			136,164				199,927
Stockholders' equity			103,948				169,237

FAQ

What were Biomea Fusion's financial results for Q2 2024?

Biomea Fusion reported a net loss of $37.3 million for Q2 2024, compared to a net loss of $24.9 million for Q2 2023.

When is the topline data readout for COVALENT-111 expected?

The topline data readout for COVALENT-111 Phase 2b trial is expected in Q4 2024.

What caused the increase in Biomea Fusion's R&D expenses for Q2 2024?

The R&D expenses increased primarily due to higher clinical and pre-clinical development costs for BMF-219 and BMF-500, and increased personnel-related costs.

What is the status of BMF-219's clinical trials?

The FDA has placed a clinical hold on BMF-219 trials for diabetes due to potential hepatotoxicity, but initial data shows promising beta-cell improvements for type 1 diabetes.

How much cash and equivalents does Biomea Fusion have as of June 30, 2024?

As of June 30, 2024, Biomea Fusion had cash, cash equivalents, and restricted cash of $113.7 million.